Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Heatwave
Char Dham Yatra
Gyanvapi Mosque
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / India News / US looking to produce of J&J's COVID-19 vaccine in India
India

US looking to produce of J&J's COVID-19 vaccine in India

US looking to produce of J&J's COVID-19 vaccine in India
Written by Tulika Chaturvedi
May 13, 2021, 02:16 am 3 min read
US looking to produce of J&J's COVID-19 vaccine in India
The US is in talks with the Serum Institute of India to boost vaccine production.

The United States is considering the production of Johnson & Johnson's COVID-19 vaccine in India along with ways to help manufacturers like the Serum Institute of India (SII) to boost production, Daniel B Smith, Charge d'Affaires of the US Embassy, said on Tuesday. Smith also expressed concern for India "not simply because of the humanitarian catastrophe, but the fact that it has global implications."

Assistance
Determined to encourage licensing, more production, says US official

At a press briefing, Smith said the US Development Finance Cooperation is contemplating how it could invest, supply raw material, and help produce the J&J COVID-19 vaccine in India. "We are determined to do all we can as a government to encourage licensing and more production. If there is a need for capital, we will look at...whether we can provide assistance," he said.

Domestic needs
'India's role in the production of COVID-19 vaccines critical'

The US official, who recently served as acting Secretary of State and acting Deputy Secretary of State, said that he is aware of private-sector production talks with other pharmaceutical companies that are currently underway. Noting that India's role in the production of COVID-19 vaccines is critical, he added the production levels of the SII and other manufacturing institutes were being carefully monitored.

Production
Might partner with other countries to meet shortfall: Smith

Acknowledging that India's diversion of indigenously-manufactured vaccines to address its domestic needs was "absolutely understandable," he noted that production in neighboring countries needs to be boosted. "A lot of these countries are at risk...We are looking to partner with other countries...to make up for whatever shortfall exists as a result of India's own dire need for these vaccines," he said.

Challenges
'Have to work together to address supply chain issues'

Smith said many companies that manufacture key components and raw materials are located in the United States, but others are not. There was a need to address issues regarding the supply chain, he said. "We're going to have to work together as a global community to address some of these supply chain issues and challenges that we face as we go forward," he added.

Details
Biden administration decides to not use AstraZeneca; won't be exported

Smith said the stockpile of the AstraZeneca vaccine wouldn't be exported till the Food and Drug Administration certifies its safety and efficacy. The Biden administration, he added, decided not to use the AstraZeneca jabs as it has sufficient stocks of three other vaccines, even as Public Health England recently said a single dose of AstraZeneca vaccine results in an 80% less risk of death.

Information
US, Japan had announced financial assistance for Indian vaccine manufacturer

Following a meet of the Quad leaders in March, the US DFC announced it would work with India's Biological E to produce one billion doses of COVID-19 vaccines by 2022-end, including J&J vaccines. In the landmark collaboration, it was announced that vaccines would be manufactured in India for the Indo-Pacific region with financial assistance from the US and Japan and logistical contributions from Australia.

Information
'Waiver of patent protections at WTO a complex process'

Despite support from the Biden administration, Smith cautioned that a proposal by India and South Africa for the waiver of patent protections for COVID-19 vaccines at the World Trade Organization would be a long, complex process. "The WTO is a consensus-based organization. We're going to have to negotiate this with our partners in the WTO...We're ramping up all of our efforts," he said.

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Tulika Chaturvedi
Tulika Chaturvedi
Mail
She/her. An alumna of Christ (Bengaluru) and the Asian College of Journalism, I deeply care about civic journalism and write about national developments for NewsBytes. Riddle me this: how many lightbulbs does it take to change people?
Latest
Vaccine
Johnson & Johnson
Coronavirus
Serum Institute of India
Related
Latest
IPL 2022, KKR vs LSG: KL Rahul elects to bat
IPL 2022, KKR vs LSG: KL Rahul elects to bat Sports
'Spiderhead' trailer: Suspense, treachery drive Chris Hemsworth-led thriller
'Spiderhead' trailer: Suspense, treachery drive Chris Hemsworth-led thriller Entertainment
Mushfiqur Rahim surpasses 5,000 career Test runs: Decoding the numbers
Mushfiqur Rahim surpasses 5,000 career Test runs: Decoding the numbers Sports
Triumph Tiger 1200 to debut in India on May 24
Triumph Tiger 1200 to debut in India on May 24 Auto
2022 TVS iQube e-scooter launched in India at Rs. 98,654
2022 TVS iQube e-scooter launched in India at Rs. 98,654 Auto
Vaccine
COVID-19: India logs 2,487 fresh cases, 13 more fatalities
COVID-19: India logs 2,487 fresh cases, 13 more fatalities India
COVID-19: India logs 2,858 fresh cases, 11 more fatalities
COVID-19: India logs 2,858 fresh cases, 11 more fatalities India
India: Phase-2 trials of world's first one-shot pneumococcal vaccine soon
India: Phase-2 trials of world's first one-shot pneumococcal vaccine soon India
India inching closer to launching its first dengue vaccine
India inching closer to launching its first dengue vaccine India
National Vaccination Day 2022: Know theme, history, significance
National Vaccination Day 2022: Know theme, history, significance Lifestyle
More News
Johnson & Johnson
J&J vaccine's 1cr doses ready for export after CDL nod
J&J vaccine's 1cr doses ready for export after CDL nod India
J&J's one-dose COVID-19 vaccine gets the nod in India
J&J's one-dose COVID-19 vaccine gets the nod in India India
J&J applies for EUA of COVID-19 vaccine in India
J&J applies for EUA of COVID-19 vaccine in India India
J&J withdraws vaccine approval request in India, CDSCO says
J&J withdraws vaccine approval request in India, CDSCO says India
FDA adds warning of rare reaction risk to J&J vaccine
FDA adds warning of rare reaction risk to J&J vaccine World
More News
Coronavirus
COVID-19: India logs 3,303 new cases; 39 more deaths
COVID-19: India logs 3,303 new cases; 39 more deaths India
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man India
COVID-19 vaccine precautionary dose available for 18+ from April 10
COVID-19 vaccine precautionary dose available for 18+ from April 10 India
COVID-19 survivors at risk of developing serious blood clots: Study
COVID-19 survivors at risk of developing serious blood clots: Study Technology
COVID-19: India reports 1,660 new cases, 4,100 more deaths
COVID-19: India reports 1,660 new cases, 4,100 more deaths India
More News
Serum Institute of India
COVID-19 vaccine precautionary dose service charge capped at Rs. 150
COVID-19 vaccine precautionary dose service charge capped at Rs. 150 India
DCGI approves emergency use of Covovax in children above 12
DCGI approves emergency use of Covovax in children above 12 India
Govt panel okays phase-3 trials of Covovax as booster dose
Govt panel okays phase-3 trials of Covovax as booster dose India
Only faster COVID-19 vaccinations can end pandemic: Adar Poonawalla
Only faster COVID-19 vaccinations can end pandemic: Adar Poonawalla India
SII to launch COVID-19 vaccine for children in 6 months
SII to launch COVID-19 vaccine for children in 6 months India
More News
Related
35 lakh doses of J&J COVID-19 vaccine reach Kasauli lab
35 lakh doses of J&J COVID-19 vaccine reach Kasauli lab India
Biological E-manufactured J&J's single-dose COVID-19 vaccine in India by October
Biological E-manufactured J&J's single-dose COVID-19 vaccine in India by October India
J&J partners with India's Biological E to produce COVID-19 vaccine
J&J partners with India's Biological E to produce COVID-19 vaccine India
Next News Article
Next News Article

Love India news?

Subscribe to stay updated.

India Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022